Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer.

Clin Cancer Res 2013 Jul 29;19(14):4008-16. Epub 2013 May 29.

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Purpose: Agents that target the epigenome show activity in breast cancer models. In preclinical studies, the histone deacetylase inhibitor vorinostat induces cell-cycle arrest, apoptosis, and differentiation. We evaluated biomarker modulation in breast cancer tissues obtained from women with newly diagnosed invasive disease who received vorinostat and those who did not.

Experimental Design: Tumor specimens were collected from 25 women who received up to 6 doses of oral vorinostat 300 mg twice daily and from 25 untreated controls in a nonrandomized study. Candidate gene expression was analyzed by reverse transcription PCR (RT-PCR) using the Oncotype DX 21-gene assay, and by immunohistochemistry for Ki-67 and cleaved caspase-3. Matched samples from treated women were analyzed for gene methylation by quantitative multiplex methylation-specific PCR (QM-MSP). Wilcoxon nonparametric tests were used to compare changes in quantitative gene expression levels pre- and post-vorinostat with changes in expression in untreated controls, and changes in gene methylation between pre- and post-vorinostat samples.

Results: Vorinostat was well tolerated and there were no study-related delays in treatment. Compared with untreated controls, there were statistically significant decreases in the expression of proliferation-associated genes Ki-67 (P = 0.003), STK15 (P = 0.005), and Cyclin B1 (P = 0.03) following vorinostat, but not in other genes by the Oncotype DX assay, or in expression of Ki-67 or cleaved caspase-3 by immunohistochemistry. Changes in methylation were not observed.

Conclusions: Short-term vorinostat administration is associated with a significant decrease in expression of proliferation-associated genes in untreated breast cancers. This demonstration of biologic activity supports investigation of vorinostat in combination with other agents for the management of breast cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718062PMC
July 2013
62 Reads

Publication Analysis

Top Keywords

breast cancer
16
untreated controls
12
gene methylation
8
pre- post-vorinostat
8
cleaved caspase-3
8
gene expression
8
proliferation-associated genes
8
expression proliferation-associated
8
newly diagnosed
8
ki-67 cleaved
8
vorinostat
8
short-term vorinostat
8
biomarker modulation
8
women newly
8
expression
6
breast
5
analyzed reverse
4
controls statistically
4
expression analyzed
4
decreases expression
4

Similar Publications